Inhibikase Therapeutics (IKT) EBIAT (2020 - 2024)
Historic EBIAT for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.1 million.
- Inhibikase Therapeutics' EBIAT fell 19039.62% to -$12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$27.5 million, marking a year-over-year decrease of 4462.17%. This contributed to the annual value of -$27.5 million for FY2024, which is 4462.17% down from last year.
- According to the latest figures from Q4 2024, Inhibikase Therapeutics' EBIAT is -$12.1 million, which was down 19039.62% from -$5.8 million recorded in Q3 2024.
- Inhibikase Therapeutics' EBIAT's 5-year high stood at -$421869.0 during Q2 2020, with a 5-year trough of -$12.1 million in Q4 2024.
- Its 5-year average for EBIAT is -$4.1 million, with a median of -$4.5 million in 2022.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 56674.67% in 2021, then soared by 1512.54% in 2022.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' EBIAT stood at -$1.2 million in 2020, then crashed by 317.36% to -$5.0 million in 2021, then increased by 15.13% to -$4.3 million in 2022, then rose by 2.36% to -$4.2 million in 2023, then crashed by 190.4% to -$12.1 million in 2024.
- Its EBIAT stands at -$12.1 million for Q4 2024, versus -$5.8 million for Q3 2024 and -$5.0 million for Q2 2024.